AustriaAustria

Intercell starts TD vaccine efficacy trial

06.01.2010

Vienna – Austrian firm Intercell AG has initiated a phase II efficacy trial as part of its clinical development program for the investigational travellers’ diarrhoea (TD) vaccine in India. The primary objective of the field trial is the prevention of all moderate/ severe diarrhoeal casesin which LT, LT/ST or ST toxins (ETEC) are detected. The trial will enrol about 800 travellers from the UK and Germany. The TD vaccine system is a combination of a patch containing the dry-formulated LT (heat-labile toxin from E. coli, the vaccine antigen) with a skin preparation system (SPS). The skin preparation system disrupts the upper layer of the skin and prepares it for the antigen delivery. The antigen is dissolved from the patch and diffuses into the skin by transepidermal water loss. Activated Langerhans cells take the vaccine antigen to the draining lymph nodes, where the immune response is initiated. The project is currently in the crucial phase III testing stages in about 1,800 European travellers to Latin America. Intercell expects the first results for early 2011 at the latest (more...).

AustriaAustria

17.03.2011

Vienna – Apeiron Biologics has entered into an exclusive option with the Cleveland Clinic to license a number of novel compounds that are currently in development there. The drug candidates are designed to fight cancer by...

AustriaAustria

06.02.2011

Vienna – Austrian vaccine specialist Intercell has halted the development of its travellers’ diarrhea vaccine patch after the product failed in a Phase III trial. The company’s management says it will now align its structure to...

Clinical Trial, AustriaAustria

06.02.2011

Vienna – Austrian Nabriva Therapeutics AG has recruited 210 patients for a Phase II study with its antibiotic BC-3781, a substance for treating acute bacterial skin infections. In the study, Nabriva will compare response rates of...

AustriaAustria

02.02.2011

Vienna/Darmstadt – Austrian Apeiron Biologics AG has in-licensed Merck's KgaA’s antibody-interleukin fusion protein hu14.18-IL2 for an undisclosed sum. The drug candidate, that is ready to be tested in Phase III studies, binds to...

AustriaAustria

16.12.2010

Vienna – Austrian Affiris AG has bagged EUR368.000 from the Michael J. Fox Foundation within the Parkinson’s Progression Markers Initiative for completion of preclinical development of its PD01 vaccine against Parkinson’s...

AustriaAustria

04.11.2010

Innsbruck – Cholesterol-lowering drugs widely used to prevent heart disease can also boost anti-cancer effect of interleukine-2 (IL-2) immune therapy. When added to tumour cell cultures treated with IL-2, statins dose-dependently...

Displaying results 11 to 20 out of 116

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-austria/browse/1/article/intercell-starts-td-vaccine-efficacy-trial.html

Print Magazine

Product of the week

Products

Events

All Events

Current issue

All issues